PubMed Health⌕ Search

Biomedical subjects

John S James

Publications and source records attributed to John S James.

At least 19 recordsLinked to original sources
PubMed2006

Daily news alerts selected by AIDS Treatment News: www.connotea.org/group/aidsnew.

Now you can follow treatment news as it happens at AIDSNEW, a free service of AIDS Treatment News. We select important, quality reports in medical journals, AIDS treatment sites, and the general press, and publish Web links to them, all in one place at www.connotea.org/group/aidsnew -- often on the first day the news is available anywhere. No need to subscribe, register, or log in. Just visit http://www.connotea.org/group/aidsnew -- then scroll down and click any of the titles for more information. You can use almost any computer and Web browser.

HIV Infections↗
PubMed2006

Resveratrol: why it matters in HIV.

Large doses of resveratrol (found in small amounts in red wine) made headlines recently for extending the lifespan of mice on an unhealthy diet. This and other substances found in some wines and foods may protect against cardiovascular disease or diabetes, and improve the functioning of mitochondria in cells (which could reduce certain adverse effects of HIV or the drugs used to treat it).

Animals↗
PubMed2006

Lung cancer: very high death rate with HIV, huge reduction possible with CT screening for early diagnosis.

Lung cancer has a high death rate, especially with HIV in one group of patients studied recently. Researchers are finding that most of the fatalities are due to late diagnosis; as many as 80% of the deaths from lung cancer in the general population might be prevented by CT screening to find the tumors early. The patients with HIV were often relatively healthy, so doctors did not suspect that they had cancer.

Early Diagnosis↗
PubMed2005

Medical innovation prize fund: new idea in drug development.

This proposal, now introduced in Congress as HR 417, would replace current drug marketing with system better designed to reward effective innovation. All drugs would be treated as generics immediately when approved by the FDA, and patent holders would be rewarded from a $60 billion a year award fund for innovations that actually led to better health.

Awards and Prizes↗
PubMed2005

Medical innovation and patent gridlock.

Is today's sheer multitude of biological patents (especially on genetics of human beings or human pathogens) killing medical innovation--in addition to generating prohibitive prices for vital medical care?

Drug Costs↗
PubMed2005

Medicaid cuts alert.

Here are some of the real problems of cutting cost by denying care, instead of by improving the U.S. healthcare system, one of the most inefficient in the world.

Budgets↗
PubMed2005

IOM: nevirapine study is reliable.

The Institute of Medicine re-analyzed the key study that first showed prevention of mother-to-child HIV transmission by single-dose nevirapine. The IOM released a 150-page report concluding that the study was properly conducted and its results are valid.

Clinical Trials as Topic↗
PubMed2005

DHEA access threatened?

DHEA came close to being totally banned in the U.S. in January 2005, when a new law aimed at steroids in sports took effect. Even doctors would not have been able to prescribe DHEA, and medical research on its uses would have become far more difficult. A potentially important treatment could have been lost for a long time -- and could still be lost unless people are vigilant.

Controlled Clinical Trials as Topic↗
PubMed2005

Sculptra facial treatment: new physician locator.

Dermik, the maker of Sculptra (a treatment for facial lipoatrophy, called New Fill in some countries) has created a database to help patients find physicians in their area who use the product. Our announcement also points to information from the recent Retroviruses conference on preventing the problem in the first place and avoiding the need for the treatment, by switching antiretroviral regimens if lipoatrophy starts to develop.

Cosmetic Techniques↗